AU2003256325A1 - Methods and materials for treating human papillomavirus infections - Google Patents

Methods and materials for treating human papillomavirus infections Download PDF

Info

Publication number
AU2003256325A1
AU2003256325A1 AU2003256325A AU2003256325A AU2003256325A1 AU 2003256325 A1 AU2003256325 A1 AU 2003256325A1 AU 2003256325 A AU2003256325 A AU 2003256325A AU 2003256325 A AU2003256325 A AU 2003256325A AU 2003256325 A1 AU2003256325 A1 AU 2003256325A1
Authority
AU
Australia
Prior art keywords
nucleic acid
hpv
acid molecule
sequence
library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003256325A
Other languages
English (en)
Inventor
Neil Christensen
Gary A. Clawson
Wei-Hua Pan
Diane Thiboutot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of AU2003256325A1 publication Critical patent/AU2003256325A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2003256325A 2002-06-26 2003-06-26 Methods and materials for treating human papillomavirus infections Abandoned AU2003256325A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US39179502P 2002-06-26 2002-06-26
US60/391,795 2002-06-26
US41799702P 2002-10-14 2002-10-14
US60/417,997 2002-10-14
US44906603P 2003-02-21 2003-02-21
US60/449,066 2003-02-21
PCT/US2003/020340 WO2004002416A2 (en) 2002-06-26 2003-06-26 Methods and materials for treating human papillomavirus infections

Publications (1)

Publication Number Publication Date
AU2003256325A1 true AU2003256325A1 (en) 2004-01-19

Family

ID=30003830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003256325A Abandoned AU2003256325A1 (en) 2002-06-26 2003-06-26 Methods and materials for treating human papillomavirus infections

Country Status (6)

Country Link
US (1) US7704965B2 (cg-RX-API-DMAC7.html)
EP (1) EP1539245A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005537028A (cg-RX-API-DMAC7.html)
AU (1) AU2003256325A1 (cg-RX-API-DMAC7.html)
CA (1) CA2491034A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004002416A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541822A (ja) 1999-04-14 2002-12-10 エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント 組織特異的および病原体特異的毒性物質ならびにリボザイム
JP2006523103A (ja) * 2003-02-21 2006-10-12 ザ ペン ステイト リサーチ ファウンデーション Rna干渉組成物および方法
WO2007121893A1 (en) * 2006-04-21 2007-11-01 Transgene S.A. Method for treating hpv infected patients
WO2008086556A1 (en) 2007-01-16 2008-07-24 The University Of Queensland Method of inducing an immune response
CA2619157A1 (en) * 2007-02-08 2008-08-08 Michel Serrano Anti-human papillomas virus composition
US7897833B2 (en) * 2007-04-18 2011-03-01 Kao Corporation Animal model for pigment spots
US7973211B2 (en) * 2007-04-18 2011-07-05 Kao Corporation Animal model for hyperpigmentation
CA2799205A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
CN102228698B (zh) * 2011-06-28 2013-12-18 广西医科大学附属肿瘤医院 Hpv58型治疗性复合基因疫苗及其构建方法
EP2746394A4 (en) 2011-08-19 2015-07-15 Ostrich Pharma Kk ANTIBODY AND ANTIBODY COMPOSITION
CN104404076B (zh) * 2014-11-04 2017-10-03 珠海雅马生物工程有限公司 利用锌指核酸酶敲除人乳头瘤病毒e6e7基因的方法
WO2017214449A1 (en) * 2016-06-09 2017-12-14 The Regents Of The University Of California Inhibition of e5 in hpv-infected cells
GB201817990D0 (en) * 2018-11-02 2018-12-19 Univ Of Essex Enterprise Limited Enzymatic nucleic acid molecules

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511713A (en) * 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
EP0092574B1 (en) * 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
FR2536278A1 (fr) * 1982-11-18 1984-05-25 Dupont Michele Nouvelle composition therapeutique utile notamment pour la cicatrisation des plaies
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US5876922A (en) * 1985-07-31 1999-03-02 Institute Pasteur Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections
CA1276575C (fr) * 1984-11-30 1990-11-20 Sylvie Beaudenon Sondes a papillomavirus et procede de diagnostic in vitro d'infections a papillomavirus
US5411857A (en) * 1985-07-31 1995-05-02 Institut Nationale De La Sante Probes for papillomaviruses and an in vitro diagnostic procedure for papilloma infections
WO1986005816A1 (en) * 1985-04-04 1986-10-09 Georgetown University Type-specific papillomavirus dna sequences and peptides
DE3779175D1 (de) * 1986-03-21 1992-06-25 Pasteur Institut Bestimmte, von einem papillomavirus-genom abgeleitete dns-sequenzen, deren anwendungen fuer in vitro-diagnostische zwecke und die herstellung von antigenzusammensetzungen.
US5071757A (en) * 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US4814268A (en) * 1986-10-06 1989-03-21 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US4849332A (en) * 1987-05-26 1989-07-18 Life Technologies, Inc. Human papillomavirus 35 nucleic acid hybridization probes and methods for employing the same
US4849331A (en) * 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same
US4849334A (en) * 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) * 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de) * 1987-07-11 1989-01-19 Behringwerke Ag Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
FR2629458B2 (fr) * 1987-07-31 1991-08-09 Ire Celltarg Sa Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain
CA1339596C (en) * 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
JP3019994B2 (ja) * 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
FR2632956B2 (fr) * 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
DE3826793A1 (de) * 1988-08-06 1990-03-08 Behringwerke Ag Humaner papillomvirus typ 57, seine dna und die davon kodierten proteine
CA1339729C (en) * 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5776502A (en) * 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
IT1232318B (it) * 1989-09-07 1992-01-28 Crinos Industria Farmaco Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo.
US5053024A (en) * 1989-10-23 1991-10-01 Israel Dvoretzky Application system and method for treating warts
US6174870B1 (en) * 1989-12-04 2001-01-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of papillomavirus
US5811232A (en) * 1989-12-04 1998-09-22 Isis Pharmaceuticals, Inc. Oligonucleotides for Papillomavirus
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5756282A (en) * 1989-12-04 1998-05-26 Isis Pharmaceuticals, Inc. Oligonucleotides for the diagnosis of papillomavirus
CA2052413C (en) 1990-09-28 2004-07-13 Jeffrey L. Joseph Nucleotides sequences useful as type-specific probes, pcr primers and lcr probes for the amplifications and detection of human papilloma virus, and related kits and methods
FR2670797A1 (fr) * 1990-12-20 1992-06-26 Pasteur Institut Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene.
US5219990A (en) * 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
FR2678284B1 (fr) * 1991-06-28 1993-10-08 Pasteur Institut Sequences d'adn derivees du genome du papillomavirus hpv42, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus et a la production de compositions immunogenes.
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5470577A (en) * 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
DE69324826D1 (de) * 1993-09-24 1999-06-10 Budowskij Edward I Gegen Papillomaviren wirksame 2',5'-OLIGOADENYLAT-2',3'-CYCLOPHOSPHATE und 2',5'-OLIGOADENYLATE
NZ277616A (en) * 1993-11-16 1997-12-19 Genta Inc Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphate internucleosidyl linkages
US6060456A (en) 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
WO1995014031A1 (en) * 1993-11-16 1995-05-26 Genta Incorporated Chirally enriched synthetic phosphonate oligomers
US5955597A (en) * 1993-11-16 1999-09-21 Genta, Incorporated Chirally enriched synthetic phosphate oligomers
JPH09507836A (ja) * 1993-11-16 1997-08-12 ジンタ・インコーポレイテッド 非ホスホネート・ヌクレオシジル間結合と混合したキラリティー的に純粋なホスホネート・ヌクレオシジル間結合を有する合成オリゴマー
FR2714830B1 (fr) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
AU2584395A (en) 1994-04-26 1995-11-16 Genta Incorporated Antisense oligomers for inhibiting human papillomaviruses
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5627159A (en) * 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
KR20050052548A (ko) 1994-12-24 2005-06-02 캠브리지 유니버시티 테크니칼 서비스 리미티드 자궁내막기능 또는 자궁내막기능과 관련된 기능의 개선방법
WO1996040961A1 (en) * 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5821050A (en) * 1995-07-04 1998-10-13 Isis Pharmaceuticals, Inc. Drug screening assay for antiviral activity against papillomavirus
FR2737118B1 (fr) * 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
US5824519A (en) * 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
EP0885236A1 (en) 1996-01-26 1998-12-23 Codon Pharmaceuticals, Inc. Oligonucleotide analogs
US5981173A (en) * 1996-02-14 1999-11-09 Institut Pasteur Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
WO1998004575A2 (en) 1996-07-31 1998-02-05 Gilead Sciences, Inc. Lipophilic oligonucleotide analogs
AU6536698A (en) 1997-02-24 1998-09-09 Tm Technologies, Inc. Anti-sense oligonucleotide pharmacological agents
US6084090A (en) * 1997-09-05 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus anti-sense oligonucleotides
DE69806024T2 (de) 1997-09-16 2003-02-13 Delft Diagnostic Laboratory B.V., Delft Erkennung und identifizierung von menschlichem papillomavirus durch pcr und typ-spezifischer reverser hybridisierung
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US6896888B1 (en) * 1998-04-29 2005-05-24 Boehle Andreas Treatment of papilloma virus infection using a mycobacterium
WO2000009673A1 (en) 1998-08-13 2000-02-24 Johnson & Johnson Research Pty. Limited Dnazymes and methods for treating hpv-related disorders
AU766403C (en) 1998-09-04 2004-05-27 Aventis Pasteur Limited Treatment of cervical cancer
WO2000034466A1 (en) 1998-12-07 2000-06-15 University College London Cervical cancer treatment
AU776150B2 (en) * 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
AU4028800A (en) * 1999-04-02 2000-10-23 City Of Hope Method for identifying accessible binding sites on rna
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
JP2002541822A (ja) * 1999-04-14 2002-12-10 エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント 組織特異的および病原体特異的毒性物質ならびにリボザイム
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20040209263A1 (en) * 2000-12-07 2004-10-21 Clawson Gary A. Selection of catalytic nucleic acids targeted to infectious agents
JP2004535813A (ja) * 2001-07-17 2004-12-02 ミルナー,アン,ジョセフィーヌ 遺伝子発現のサイレンシング
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
JP2006523103A (ja) * 2003-02-21 2006-10-12 ザ ペン ステイト リサーチ ファウンデーション Rna干渉組成物および方法

Also Published As

Publication number Publication date
CA2491034A1 (en) 2004-01-08
JP2005537028A (ja) 2005-12-08
WO2004002416A3 (en) 2005-02-03
WO2004002416A2 (en) 2004-01-08
US7704965B2 (en) 2010-04-27
US20060058252A1 (en) 2006-03-16
EP1539245A2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
US7704965B2 (en) Methods and materials for treating human papillomavirus infections
US5004810A (en) Antiviral oligomers
Rösl et al. Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription
US20040209263A1 (en) Selection of catalytic nucleic acids targeted to infectious agents
Storey et al. Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16
JP2002542263A (ja) ポリヌクレオチド配列の機能を阻害するための方法および組成物
JP2023013932A (ja) SARS-CoV-2 RNA配列に基づく新規siRNA及びその利用
WO2000009673A1 (en) Dnazymes and methods for treating hpv-related disorders
JP6727381B2 (ja) Hpv感染に係わる癌の治療用組成物
CA2226457C (en) Oligonucleotides specific for human papilloma virus
CA2516425A1 (en) Rna interference compositions and methods
EP0656942A1 (en) Compositions and methods for inhibiting growth or replication of viruses
Márquez-Gutiérrez et al. Effect of combined antisense oligodeoxynucleotides directed against the human papillomavirus type 16 on cervical carcinoma cells
CN115400222A (zh) 一种用于人乳头状瘤病毒感染治疗和预防的核酸多肽纳米药物组合物
JPH09509323A (ja) 疾患関連遺伝子の発現を阻害するための方法および試薬
JP2004501614A (ja) Hpv特異的ショートマー
AU2002228756B2 (en) Selection of catalytic nucleic acids targeted to infectious agents
EP0759992B1 (en) Human papilloma virus inhibition by a hairpin ribozyme
JP2011190176A (ja) 肥満細胞の脱顆粒抑制剤
US20030055240A1 (en) HPV specific oligonucleotides
AU2002228756A1 (en) Selection of catalytic nucleic acids targeted to infectious agents
WO1995024477A1 (en) Human papillomavirus targeted ribozymes
WO2011046221A1 (ja) インターフェロン-αモジュレーター

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application